Kiora Pharmaceuticals (NASDAQ:KPRX) Issues Quarterly Earnings Results

Kiora Pharmaceuticals (NASDAQ:KPRX) announced its quarterly earnings data on Friday. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.13, FiscalAI reports.

Kiora Pharmaceuticals Stock Up 3.1%

KPRX traded up $0.08 on Friday, reaching $2.64. 23,543 shares of the company traded hands, compared to its average volume of 22,446. Kiora Pharmaceuticals has a one year low of $1.76 and a one year high of $3.01. The firm has a fifty day simple moving average of $2.57 and a two-hundred day simple moving average of $2.37. The company has a market cap of $11.70 million, a P/E ratio of -0.97 and a beta of -0.38.

Institutional Investors Weigh In On Kiora Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Alyeska Investment Group L.P. purchased a new stake in Kiora Pharmaceuticals in the fourth quarter worth about $152,000. DRW Securities LLC increased its holdings in Kiora Pharmaceuticals by 199.2% during the fourth quarter. DRW Securities LLC now owns 110,282 shares of the company’s stock valued at $217,000 after buying an additional 73,417 shares during the period. Citadel Advisors LLC purchased a new position in Kiora Pharmaceuticals during the third quarter valued at approximately $125,000. Two Sigma Investments LP bought a new position in Kiora Pharmaceuticals in the third quarter worth approximately $33,000. Finally, Renaissance Technologies LLC raised its stake in Kiora Pharmaceuticals by 71.0% in the fourth quarter. Renaissance Technologies LLC now owns 21,200 shares of the company’s stock worth $42,000 after buying an additional 8,800 shares in the last quarter. 76.97% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded Kiora Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 14th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $10.00.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.